Pharmacogenomics and antidepressants: efficacy and adverse drug reactions

Joseph F. Goldberg, Charles B. Nemeroff

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

Pharmacogenetics has gained increasing interest among both clinicians and investigators as a potentially useful tool for gauging psychotropic drug trial outcomes. Strides have been made in identifying polymorphic loci associated with poor metabolizer genotypes of Phase I (i.e., cytochrome P450) hepatic enzymes, which, in turn, may account for some proportions of adverse drug effects or poor conversion of prodrugs or parent compounds to active metabolites; or ultrarapid metabolizer genotypes for whom standard drug dosages may be subtherapeutic. Particular adverse drug effects also have been linked with unique susceptibility genes, such as an increased risk for Stevens Johnson syndrome following carbamazepine treatment in Southeast Asians who carry the HLA*B1502 gene. Less well established are the use of functional polymorphisms of candidate genes associated with neurotransmitter function (such as the serotonin transporter gene, locus SLC6A4), or combinatorial pharmacogenetic groupings of genes, in order to predict pharmacodynamic efficacy of antidepressants. Herein we review current evidence for the practical application of psychiatric pharmacogenetic testing at the bedside, noting strengths, weaknesses, areas of uncertainty, and directions for future work.

Original languageEnglish
Title of host publicationPsychiatric Genomics
PublisherElsevier
Pages189-202
Number of pages14
ISBN (Electronic)9780128196021
ISBN (Print)9780128214008
DOIs
StatePublished - 1 Jan 2022

Keywords

  • Pharmacogenetics
  • SLC6A4
  • adverse drug reactions
  • antidepressants
  • efficacy
  • genotype
  • pharmacogenomics

Fingerprint

Dive into the research topics of 'Pharmacogenomics and antidepressants: efficacy and adverse drug reactions'. Together they form a unique fingerprint.

Cite this